Ranoxen Plus 500 Tablet

RanoxenTM Plus 500 Tablet: Each tablet contains Naproxen Sodium USP equivalent to Naproxen 500 mg and Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 20 mg.

It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, dysmenorrhea and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAIDs associated gastric ulcers.

Carefully consider the potential benefits and risks of RanoxenTM Plus (Naproxen and Esomeprazole) and other treatment options before deciding to use RanoxenTM Plus (Naproxen and Esomeprazole). Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. If a dose of Esomeprazole lower than a total daily dose of 40 mg is more appropriate, a different treatment should be considered. For Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis: The dosage is one tablet twice daily of 375 mg Naproxen and 20 mg of Esomeprazole or 500 mg Naproxen and 20 mg of Esomeprazole.* Do not split, chew, crush or dissolve the tablet. RanoxenTM Plus (Naproxen and Esomeprazole) is to be taken at least 30 minutes before meals. Geriatric Patients: Studies indicate that although total plasma concentration of Naproxen is unchanged, the unbound plasma fraction of Naproxen is increased in the elderly. Use caution when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly use the lowest effective dose. Patients with Moderate to Severe Renal Impairment: Naproxen containing products are not recommended for use in patients with moderate to severe or severe renal impairment (creatinine clearance<30 mL/min). Hepatic Insufficiency: Monitor patients with mild to moderate hepatic impairment closely and consider a possible dose reduction based on the Naproxen component of RanoxenTM Plus (Naproxen and Esomeprazole). RanoxenTM Plus (Naproxen and Esomeprazole) is not recommended in patients with severe hepatic impairment because Naproxen may increase the risk of renal failure or bleeding and Esomeprazole doses should not exceed 20 mg daily in these patients.